Imcivree approved by European Commission for treatment of obesity and control of hunger in Bardet-Biedl syndrome
Rhythm Pharmaceuticals, Inc. announced that the European Commission (EC) has expanded the marketing authorization for Imcrivee (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older
“Patients and families have long endured a significant need for a therapy to address the burdens of hyperphagia and severe obesity often associated with BBS,” said Philip Beales, M.D., University College London, UCL Great Ormond Street Institute of Child Health. “Having new treatment options available can help address the physical and emotional aspects of this devastating disease, offering patients and their families relief and improved quality of life.”
BBS is a rare genetic disease that affects approximately 2,500 people in the European Union (EU) and United Kingdom (UK). People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life. Approximately 1,500 patients have been diagnosed with BBS and are now being cared for at academic settings in the EU and UK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins